Novo Nordisk

Latest Headlines

Latest Headlines

Novo's blockbuster diabetes combo nears EU approval

A committee of European Medicines Agency advisers is recommending approval for Novo Nordisk's combination of a long-acting insulin and its blockbuster GLP-1 drug Victoza, setting the stage for a near-term approval of what's expected to be the diabetes giant's next big therapy.

Novo A/S-owned Xellia snaps up Fresenius vial plant to expand in U.S.

The deal gives Xellia capacity in North America for the first time, providing the company with a platform from which to realize the mid-term growth opportunities envisaged by Novo A/S when it bought the company.

Novo Nordisk can double sales in a decade, deputy CEO says

So far, 2014 hasn't been the best year for Denmark's Novo Nordisk. The perenially fast-growing drugmaker saw sales growth slip into the single digits for the first quarter.

Novo Nordisk new insulin pen to stimulate U.S. demand

U.S. diabetes patients are much more likely to use a vial and syringe than Europeans, who prefer a prefilled pen. Diabetes powerhouse Novo Nordisk is looking to remedy that situation with the introduction of a new, easier-to-use pen onto the U.S. market: the Levemir FlexTouch.

What's next in diabetes drugs? The pulse of R&D at ADA14

Convening in San Francisco for the annual conference of the American Diabetes Association this weekend, drugmakers angled for the spotlight in a field made up mostly of similar treatments with small differentiations that could spell the difference between blockbuster sales and also-ran status.

Novo touts one-year data for its diabetes tandem therapy

Combine the blockbuster GLP-1 drug Victoza with a long-acting insulin and you get a treatment greater than the sum of its parts, according to Novo Nordisk, which unveiled promising new data on its diabetes cocktail IDegLira.

Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production

Novo Nordisk has been staffing up its sales and marketing teams in the U.S. at a time when bigger rivals are cutting back. Turns out, the Danish drugmaker has big plans for expansion back home as well.

Group again petitions FDA to ban Novo Nordisk's Victoza

While Victoza brought in more than $2 billion last year, it has been dogged by concerns that it raises the risk of pancreatitis--and despite it and other similar drugs being cleared by reviews by both the FDA and EU regulators this year, some keep pushing the FDA to consider pulling it off the market.

With new hopes for German pricing, Novo Nordisk decides to roll out Tresiba there

Novo Nordisk has decided to play ball in Germany. The Danish drugmaker now plans to launch its brand-new diabetes drug Tresiba in that country, despite a notorious pricing policy that Novo feared would interfere with its success.

Need a job? J&J, Novartis and Biogen Idec are pharma's favorite employers

With all of the pharma layoffs, lots of folks are looking for a job in the industry. So where are the best places to work? Johnson & Johnson and Novartis if you want to work for a large company. Biogen Idec, Gilead or perhaps Novo Nordisk if you prefer more of a midsize drugmaker.